申論題內容
8. The risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent therapy with
erythromycin, cyclosporine. or fibrate. Pravastatin (F = 0.17) is HMG-CoA reductase inhibitor and is a substrate of OATPI B1.
Explain the impacts of the changes in the OATP I BI activity on the therapeutic efficacy and myopathy of pravastatin.
respectively.(5 points)
阿摩線上測驗
登入